Cellectar Biosciences Secures New Patents in Europe, Asia-Pacific, Middle East and Americas Ahead of 3Q26 EMA Filing
Cellectar Biosciences secured new patents for its radiotherapeutics across Europe, Asia-Pacific, the Middle East and the Americas, covering iopofosine I-131 and CLR-125’s therapeutic and imaging applications. The expanded IP estate paves the way for its 3Q26 conditional marketing authorization filing with the EMA for iopofosine I-131 in Waldenström macroglobulinemia.
1. Patent Expansion Across Key Regions
Cellectar Biosciences has secured newly issued patents for its radiotherapeutic iopofosine I-131 and its Auger-emitting agent CLR-125. The expanded IP includes patents for ether and alkyl phospholipid compounds treating and imaging cancer stem cells, plus separate patents covering fractionated dosing regimens in Europe, Asia-Pacific, the Middle East, the Americas, Eurasia, Israel, Turkey, Mexico, Canada and New Zealand.
2. Planned 3Q26 EMA Filing for Waldenström Macroglobulinemia
Following guidance from the EMA’s Scientific Advice Working Party, Cellectar plans to file a conditional marketing authorization application in 3Q26 for iopofosine I-131 as a treatment for Waldenström macroglobulinemia. Strengthened patent protection in major European markets underpins this regulatory milestone.
3. Strategic and Commercial Implications
The broader patent coverage fortifies Cellectar’s long-term commercial strategy by protecting its proprietary Phospholipid Drug Conjugate (PDC) platform from generic competition. Enhanced global IP bolsters potential partnerships and supports future revenue streams upon approval of its radiotherapeutic portfolio.